Spots Global Cancer Trial Database for gbm
Every month we try and update this database with for gbm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | NCT04869449 | Glioblastoma Glioblastoma Mu... Glioblastoma Mu... Glioblastoma Mu... | Ketoconazole | 18 Years - | Milton S. Hershey Medical Center | |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | NCT05954858 | Glioma, Maligna... Glioblastoma Glioblastoma Mu... Glioblastoma Mu... High Grade Glio... GBM Brain Cancer | Tissue autograf... | 18 Years - | Northwell Health | |
| Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | NCT00302159 | High Grade Glio... Brain Tumors | adjuvant therap... Temozolomide Valproic Acid Radiation thera... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | NCT04471844 | Glioblastoma Mu... | Optune® | 18 Years - | NovoCure Ltd. | |
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | NCT00290771 | Recurrent Gliob... | Imatinib tablet... Hydroxyurea cap... | 18 Years - | Novartis | |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | NCT03451799 | GBM Glioblastoma | Ketogenic Diet Standard-of-car... Standard-of-car... | 18 Years - | Cedars-Sinai Medical Center | |
| Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin | NCT05977738 | Glioblastoma Mu... Recurrent Gliob... | Pitavastatin ca... | 18 Years - | Erasmus Medical Center | |
| Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) | NCT00797940 | Glioblastoma Mu... | IL-4PE | 18 Years - | Protox Inc. | |
| Bevacizumab With or Without Surgery for Adult Glioblastomas | NCT01413438 | Glioblastoma Brain Neoplasm | Craniotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) | NCT06147505 | Glioblastoma GBM | XS005 Cell Inje... Temozolomide（TM... | 18 Years - 70 Years | Dushu Lake Hospital Affiliated to Soochow University | |
| A Single Patient Compassionate Use Clinical Trial for the Use of L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment Diffuse Midline Glioma, H3 K27/28-altered (DMG), Including Diffuse Intrinsic Pontine Glioma (DIPG) | NCT06439849 | DIPG Brain Tumo... Diffuse Brainst... H3 K27M H3 K28M GBM | S-Gboxin | - | Petrov, Andrey | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma | NCT03119064 | Glioblastoma Mu... Glioblastoma GBM | Nanoliposomal I... Temozolomide | 18 Years - | Brown University | |
| Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | NCT00376103 | Glioblastoma Mu... | temozolomide Brachytherapy External Beam R... | 18 Years - | Methodist Healthcare | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | NCT05267106 | Glioblastoma Adult-type Diff... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients | NCT02623231 | GBM Depression | Escitalopram placebo | 18 Years - 80 Years | Tel-Aviv Sourasky Medical Center | |
| PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | NCT01112527 | Glioblastoma GBM Glioblastoma Mu... | PF-00299804 | 18 Years - | Massachusetts General Hospital | |
| A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | NCT00990496 | Glioblastoma Mu... | Fludarabine Cyclophosphamid... CMV Specific Cy... | 5 Years - 65 Years | Milton S. Hershey Medical Center | |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | NCT05868083 | Recurrent Gliob... | SNC-109 CAR-T C... | 18 Years - 70 Years | Shanghai Simnova Biotechnology Co.,Ltd. | |
| Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | NCT05973903 | GBM | Lenvatinib Pembrolizumab Tumor Treating ... | 18 Years - | Tel Aviv Medical Center | |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | NCT03630289 | Glioblastoma Glioblastoma Mu... GBM Brain Cancer | Tissue autograf... | 18 Years - | Northwell Health | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | NCT04763031 | Glioblastoma GBM Recurrent GBM | Intra-operative... | 18 Years - | Parkridge Medical Center | |
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | NCT01257594 | Brain Cancer | erlotinib Cytoreductive S... | 18 Years - | Columbia University | |
| A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma | NCT00660283 | Glioma | Temozolomide | 18 Years - 75 Years | Kentuckiana Cancer Institute | |
| A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | NCT05053880 | Recurrent Gliob... | ACT001 ACT001 + Pembro... | 18 Years - | Accendatech USA Inc. | |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | NCT05271240 | Glioblastoma Glioblastoma Mu... Glioma, Maligna... GBM Brain Cancer Glioblastoma, I... Glioblastoma Mu... | Repeated Supers... Temozolomide an... | 18 Years - | Northwell Health | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | NCT01349660 | Glioblastoma Mu... | Bevacizumab BKM120 | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | NCT04478279 | Glioblastoma Melanoma Stage ... Breast Cancer Prostate Cancer Glioblastoma Mu... GBM Brain Cancer Metastatic Brea... Metastatic Mela... Metastatic Pros... Melanoma Recurr... Prostate Cancer... Recurrent Gliob... Newly Diagnosed... | ST101 Temozolomide Radiation | 18 Years - | Sapience Therapeutics | |
| A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | NCT01752491 | Glioblastoma GBM Glioblastoma Mu... | Ascorbate Temozolomide Radiation thera... | 18 Years - | University of Iowa | |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | NCT01238237 | Glioblastoma Mu... ANAPLASTIC ASTR... GBM Anaplastic Astr... | Superselective ... | 18 Years - | Northwell Health | |
| Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | NCT03426891 | Glioblastoma Brain Tumor GBM | Pembrolizumab Vorinostat Temozolomide Radiotherapy | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | NCT04471844 | Glioblastoma Mu... | Optune® | 18 Years - | NovoCure Ltd. | |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | NCT01906385 | Glioma | Rhenium Liposom... | 18 Years - | Plus Therapeutics | |
| Study of Immunotoxin, MR1-1 | NCT01009866 | Supratentorial ... | MR1-1 | 18 Years - | Duke University | |
| The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | NCT00076986 | Glioblastoma Mu... | IL13-PE38QQR surgery and cat... prolifespan 20 ... surgery and waf... | 18 Years - | INSYS Therapeutics Inc | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | NCT00376103 | Glioblastoma Mu... | temozolomide Brachytherapy External Beam R... | 18 Years - | Methodist Healthcare | |
| Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | NCT00548938 | Glioblastoma Mu... High-Grade Glio... | Gliadel wafer Temozolomide External Beam R... | 18 Years - 72 Years | Methodist Healthcare | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence | NCT01526837 | Glioblastoma Mu... | Avastin | 18 Years - | Brain & Spine Surgeons of New York | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | NCT05902169 | Glioblastoma Recurrent Gliob... GBM | SonoCloud-9 (SC... Carboplatin Lomustine Temozolomide | 18 Years - | CarThera | |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | NCT04869449 | Glioblastoma Glioblastoma Mu... Glioblastoma Mu... Glioblastoma Mu... | Ketoconazole | 18 Years - | Milton S. Hershey Medical Center | |
| Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT) | NCT01854554 | Brain Cancer | IMPT IMRT Cognitive Tests Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluating Tumor Pseudoprogression With FLT-PET and MRI | NCT01105988 | Glioblastoma | Radiologic exam... | 18 Years - | Massachusetts General Hospital | |
| Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | NCT03223103 | Glioblastoma | Poly-ICLC Tumor Treating ... Peptides | 18 Years - | Albert Einstein College of Medicine | |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | NCT05076513 | Glioblastoma Glioblastoma Mu... Glioma GBM Glioma, Maligna... Glioblastoma Mu... | Niraparib Radiation thera... | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | NCT05053880 | Recurrent Gliob... | ACT001 ACT001 + Pembro... | 18 Years - | Accendatech USA Inc. | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | NCT05271240 | Glioblastoma Glioblastoma Mu... Glioma, Maligna... GBM Brain Cancer Glioblastoma, I... Glioblastoma Mu... | Repeated Supers... Temozolomide an... | 18 Years - | Northwell Health | |
| Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | NCT02085304 | Glioblastoma | Gross total res... GammaKnife(R) s... Standard fracti... Temozolomide | 18 Years - 80 Years | St. Joseph's Hospital and Medical Center, Phoenix | |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM | NCT03149575 | Glioblastoma Mu... Glioblastoma Glioma GBM Brain Cancer | VAL-083, Dianhy... Physician's Cho... Physician's Cho... Physician's Cho... | 18 Years - | Kintara Therapeutics, Inc. | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | NCT03050736 | Glioma Glioblastoma Glioblastoma Mu... GBM Brain Cancer | VAL-083 (Dianhy... | 18 Years - 69 Years | Kintara Therapeutics, Inc. | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma | NCT05879367 | Glioblastoma, I... Glioblastoma Glioblastoma Mu... Glioblastoma ID... GBM | Eflornithine (D... Eflornithine (D... Eflornithine (D... Temozolomide | 18 Years - | Orbus Therapeutics, Inc. | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma | NCT02715297 | Glioblastoma | SRT to the rese... | 18 Years - 99 Years | Technical University of Munich | |
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | NCT00704288 | Glioblastoma Mu... | XL184 | 18 Years - | Exelixis | |
| Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM | NCT04195139 | Glioblastoma Mu... | Nivolumab Temozolomide | 65 Years - | University of Sydney |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
